Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Functional assessment of hematopoietic niche cells derived from human embryonic stem cells.

Ferrell PI, Hexum MK, Kopher RA, Lepley MA, Gussiaas A, Kaufman DS.

Stem Cells Dev. 2014 Jun 15;23(12):1355-63. doi: 10.1089/scd.2013.0497. Epub 2014 Mar 11.


Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.

Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS.

Stem Cells Transl Med. 2013 Apr;2(4):274-83. doi: 10.5966/sctm.2012-0084. Epub 2013 Mar 20.


Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA.

Mol Cancer Ther. 2011 Oct;10(10):1829-38. doi: 10.1158/1535-7163.MCT-11-0206. Epub 2011 Aug 23.


In vivo evaluation of putative hematopoietic stem cells derived from human pluripotent stem cells.

Hexum MK, Tian X, Kaufman DS.

Methods Mol Biol. 2011;767:433-47. doi: 10.1007/978-1-61779-201-4_32.


Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms.

Ni Z, Knorr DA, Clouser CL, Hexum MK, Southern P, Mansky LM, Park IH, Kaufman DS.

J Virol. 2011 Jan;85(1):43-50. doi: 10.1128/JVI.01774-10. Epub 2010 Oct 20.


Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34(+) cells preferentially develop into endothelial cells.

Tian X, Hexum MK, Penchev VR, Taylor RJ, Shultz LD, Kaufman DS.

Stem Cells. 2009 Nov;27(11):2675-85. doi: 10.1002/stem.204.

Supplemental Content

Loading ...
Support Center